{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:13:50Z","timestamp":1763018030057},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the influence of the fellow-eye examination interval on visual acuity at fellow-eye neovascularization in unilateral Type 3 neovascularization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective, observational study included 55 patients who were initially diagnosed with unilateral Type 3 neovascularization and subsequently developed fellow-eye neovascularization during the follow-up period. The fellow-eye examination interval was defined as the hospital visit interval between fellow-eye neovascularization detection and immediately before neovascularization detection. The primary outcome measures were the associations between the fellow-eye examination interval and fellow-eye best-corrected visual acuity (BCVA) at fellow-eye neovascularization detection and degree of deterioration in fellow-eye BCVA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>After the initial diagnosis of the first-involved eye, fellow-eye neovascularization was noted after a period of 22.7 \u00b1 17.5 months. The mean fellow-eye examination interval was 4.8 \u00b1 2.2 months (range, 2\u201310 months). The mean logarithm of the minimum angle of resolution BCVA in the fellow eye was 0.22 \u00b1 0.18 (Snellen equivalents, 20\/33) immediately before neovascularization and 0.52 \u00b1 0.26 (20\/66) at neovascularization. There were significant associations between the fellow-eye examination interval and fellow-eye BCVA when neovascularization was detected (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.005, r = 0.371) and at degree of deterioration in fellow-eye BCVA (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001, r = 0.428).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>A longer fellow-eye examination interval was associated with poor visual acuity and greater visual deterioration of the fellow eye at neovascularization. These results suggest the need for frequent fellow-eye examination in patients with unilateral Type 3 neovascularization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002603","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T13:11:56Z","timestamp":1561468316000},"page":"1255-1261","source":"Crossref","is-referenced-by-count":7,"title":["INFLUENCE OF FELLOW-EYE EXAMINATION INTERVAL ON VISUAL ACUITY AT FELLOW-EYE NEOVASCULARIZATION IN UNILATERAL TYPE 3 NEOVASCULARIZATION"],"prefix":"10.1097","volume":"40","author":[{"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230817","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2003.05.010","article-title":"Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study","volume":"111","author":"Buch","year":"2004","journal-title":"Ophthalmology"},{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R3-20230817","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.7647","article-title":"The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration","volume":"132","author":"Sloan","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R4-20230817","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-Year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"R5-20230817","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.ophtha.2016.07.015","article-title":"Distinguishing between better and worse visual acuity by studying the correlation with quality of life in neovascular age-related macular degeneration","volume":"123","author":"Elshout","year":"2016","journal-title":"Ophthalmology"},{"key":"R6-20230817","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","article-title":"Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP study)","volume":"123","author":"Bhisitkul","year":"2016","journal-title":"Ophthalmology"},{"key":"R7-20230817","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/eye.2016.324","article-title":"Neovascular age-related macular degeneration: is it worthwhile treating an eye with poor visual acuity, if the visual acuity of the fellow eye is good?","volume":"31","author":"Rasmussen","year":"2017","journal-title":"Eye (Lond)"},{"key":"R8-20230817","doi-asserted-by":"crossref","article-title":"Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization","author":"Kim","DOI":"10.1097\/IAE.0000000000002239"},{"key":"R9-20230817","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.ophtha.2013.03.017","article-title":"Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Maguire","year":"2013","journal-title":"Ophthalmology"},{"key":"R10-20230817","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jamaophthalmol.2018.2154","article-title":"Incidence of fellow eye involvement in patients with unilateral exudative age-related macular degeneration","volume":"136","author":"Yanagi","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R11-20230817","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaophthalmol.2018.1534","article-title":"Outcomes of anti-vascular endothelial growth factor treatment for choroidal neovascularization in fellow eyes of previously treated patients with neovascular age-related macular degeneration","volume":"136","author":"Stem","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R12-20230817","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-20230817","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R14-20230817","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","article-title":"Ranibizumab according to need: a treatment for age-related macular degeneration","volume":"143","author":"Spaide","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R15-20230817","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","article-title":"\u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation","volume":"29","author":"Engelbert","year":"2009","journal-title":"Retina"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/IAE.0b013e3181669504","article-title":"Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation","volume":"28","author":"Freund","year":"2008","journal-title":"Retina"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","article-title":"Retinal angiomatous proliferation in age-related macular degeneration","volume":"21","author":"Yannuzzi","year":"2001","journal-title":"Retina"},{"key":"R18-20230817","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006982-200509000-00005","article-title":"Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation","volume":"25","author":"Gross","year":"2005","journal-title":"Retina"},{"key":"R19-20230817","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1111\/aos.12748","article-title":"Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population","volume":"94","author":"Chang","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R20-20230817","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/01.iae.0000434566.57189.37","article-title":"Incidence and characteristics of neovascularization in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation","volume":"34","author":"Sawa","year":"2014","journal-title":"Retina"},{"key":"R21-20230817","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","article-title":"Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography","volume":"35","author":"Nagiel","year":"2015","journal-title":"Retina"},{"key":"R22-20230817","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcrs.2004.01.014","article-title":"Visual acuity measurements","volume":"30","author":"Holladay","year":"2004","journal-title":"J Cataract Refract Surg"},{"key":"R23-20230817","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00417-010-1520-9","article-title":"Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity","volume":"249","author":"Muether","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-20230817","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/IAE.0b013e3182018df6","article-title":"Time to first treatment: the significance of early treatment of exudative age-related macular degeneration","volume":"32","author":"Rauch","year":"2012","journal-title":"Retina"},{"key":"R25-20230817","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","article-title":"Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment","volume":"123","author":"Mueller","year":"2016","journal-title":"Ophthalmology"},{"key":"R26-20230817","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cct.2014.02.003","article-title":"Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design\u2014HOME Study report number 1","volume":"37","author":"Chew","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"R27-20230817","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ophtha.2013.10.027","article-title":"Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"R28-20230817","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:14:12Z","timestamp":1692234852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002603","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}